Close Menu

NEW YORK (GenomeWeb) – Genentech will sequence the whole genomes of 3,000 people from 23andMe's Parkinson's disease community in an effort to identify drug targets, the companies announced today.

Under the terms of the deal, 23andMe will be able to conduct additional research on the generated data once the project is completed. Additionally, 23andMe can share the data, scrubbed of patients' identifying information, with other researchers. Only data from 23andMe customers who have consented to participate in the research will be shared, 23andMe said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.

Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.

Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.

In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.